Advertisement

Melatonin

  • Roberta M. Leu
Chapter

Abstract

Supplemental melatonin is one of the most commonly recommended biomedical agents for difficulty falling asleep or maintaining sleep in children with neurodevelopmental disorders. This chapter provides an overview of melatonin, its synthesis, and its biological properties. Dosing of melatonin in sleep disorders, its pharmacokinetics, side effects, and potential drug interactions are discussed. Available data on the use of melatonin for sleep in specific neurodevelopmental populations including autism, attention-deficit/hyperactivity disorder, Angelman syndrome, Rett syndrome, fragile X syndrome, tuberous sclerosis, epilepsy, and traumatic brain injury is reviewed.

Keywords

Melatonin Circadian rhythm Autism Attention-deficit/hyperactivity disorder Angelman syndrome Rett syndrome Fragile X syndrome Tuberous sclerosis Epilepsy Traumatic brain injury Insomnia Sleep problems 

References

  1. 1.
    Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem. 1960;235:1992–7.PubMedGoogle Scholar
  2. 2.
    Chen YC, Tain YL, Sheen JM, Huang LT. Melatonin utility in neonates and children. J Formos Med Assoc. 2012;111(2):57–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Leu RM, Beyderman L, Botzolakis EJ, Surdyka K, Wang L, Malow BA. Relation of melatonin to sleep architecture in children with autism. J Autism Dev Disord. 2011;41(4):427–33.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Sajith SG, Clarke D. Melatonin and sleep disorders associated with intellectual disability: a clinical review. J Intellect Disabil Res. 2007;51(Pt 1):2–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD, et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007;31(1):1–11.CrossRefGoogle Scholar
  6. 6.
    Doyen C, Mighiu D, Kaye K, Colineaux C, Beaumanoir C, Mouraeff Y, et al. Melatonin in children with autistic spectrum disorders: recent and practical data. Eur Child Adolesc Psychiatry. 2011;20(5):231–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Maldonado MD, Murillo-Cabezas F, Terron MP, Flores LJ, Tan DX, Manchester LC, et al. The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma. J Pineal Res. 2007;42(1):1–11.PubMedCrossRefGoogle Scholar
  8. 8.
    DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino JS Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40(7):781–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998;12(12):1211–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Palm L, Blennow G, Wetterberg L. Correction of non-24-hour sleep/wake cycle by melatonin in a blind retarded boy. Ann Neurol. 1991;29(3):336–9.PubMedCrossRefGoogle Scholar
  11. 11.
    McArthur AJ, Budden SS. Sleep dysfunction in Rett syndrome: a trial of exogenous melatonin treatment. Dev Med Child Neurol. 1998;40(3):186–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2–4 hours before habitual bedtime, on sleep in normal young humans. Sleep. 1996;19(5):423–31.PubMedCrossRefGoogle Scholar
  13. 13.
    Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. Res Dev Disabil. 2011;32(3):939–62.PubMedCrossRefGoogle Scholar
  14. 14.
    Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol. 1985;19(4):517–21.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Braam W, van Geijlswijk I, Keijzer H, Smits MG, Didden R, Curfs LM. Loss of response to melatonin treatment is associated with slow melatonin metabolism. J Intellect Disabil Res. 2010;54(6):547–55.PubMedCrossRefGoogle Scholar
  16. 16.
    Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab. 1996;81(5):1882–6.PubMedGoogle Scholar
  17. 17.
    Grigg-Damberger M, Ralls F. Treatment strategies for complex behavioral insomnia in children with neurodevelopmental disorders. Curr Opin Pulm Med. 2013;19(6):616–25.PubMedCrossRefGoogle Scholar
  18. 18.
    Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–81.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Owens JA, Moturi S. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009;18(4):1001–16.PubMedCrossRefGoogle Scholar
  20. 20.
    Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract. 2007;61(5):835–45.PubMedCrossRefGoogle Scholar
  21. 21.
    Damiani JM, Sweet BV, Sohoni P. Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am J Health Syst Pharm. 2014;71(2):95–101.PubMedCrossRefGoogle Scholar
  22. 22.
    Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9(5):380–92.PubMedCrossRefGoogle Scholar
  23. 23.
    Lewy AJ, Emens JS, Sack RL, Hasler BP, Bernert RA. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649–58.PubMedCrossRefGoogle Scholar
  24. 24.
    Jan JE, O’Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. J Pineal Res. 1996;21(4):193–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ayyash HF, Preece P, Morton R, Cortese S. Melatonin for sleep disturbance in children with neurodevelopmental disorders: prospective observational naturalistic study. Expert Rev Neurother. 2015;15(6):711–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Coppola G, Iervolino G, Mastrosimone M, La Torre G, Ruiu F, Pascotto A. Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development. 2004;26(6):373–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Gringras P, Gamble C, Jones AP, Wiggs L, Williamson PR, Sutcliffe A, et al. Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial. BMJ. 2012;345:e6664.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42(8):1729–37; author reply 38.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Carr R, Wasdell MB, Hamilton D, Weiss MD, Freeman RD, Tai J, et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007;43(4):351–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008;23(5):482–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Braam W, Keijzer H, Struijker Boudier H, Didden R, Smits M, Curfs L. CYP1A2 polymorphisms in slow melatonin metabolisers: a possible relationship with autism spectrum disorder? J Intellect Disabil Res. 2013;57(11):993–1000.PubMedGoogle Scholar
  32. 32.
    Johnson KP, Malow BA. Assessment and pharmacologic treatment of sleep disturbance in autism. Child Adolesc Psychiatr Clin N Am. 2008;17(4):773–85, viii.PubMedCrossRefGoogle Scholar
  33. 33.
    Hoebert M, van der Heijden KB, van Geijlswijk IM, Smits MG. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. 2009;47(1):1–7.PubMedCrossRefGoogle Scholar
  34. 34.
    O’Callaghan FJ, Clarke AA, Hancock E, Hunt A, Osborne JP. Use of melatonin to treat sleep disorders in tuberous sclerosis. Dev Med Child Neurol. 1999;41(2):123–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther. 1983;227(3):587–91.PubMedGoogle Scholar
  36. 36.
    Seabra ML, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. 2000;29(4):193–200.PubMedCrossRefGoogle Scholar
  37. 37.
    Miyamoto A, Oki J, Takahashi S, Okuno A. Serum melatonin kinetics and long-term melatonin treatment for sleep disorders in Rett syndrome. Brain and Development. 1999;21(1):59–62.PubMedCrossRefGoogle Scholar
  38. 38.
    Wright B, Sims D, Smart S, Alwazeer A, Alderson-Day B, Allgar V, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord. 2011;41(2):175–84.PubMedCrossRefGoogle Scholar
  39. 39.
    Guenole F, Godbout R, Nicolas A, Franco P, Claustrat B, Baleyte JM. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev. 2011;15(6):379–87.PubMedCrossRefGoogle Scholar
  40. 40.
    Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 2014;15(10):17920–37.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Marseglia L, D'Angelo G, Manti S, Salpietro C, Arrigo T, Barberi I, et al. Melatonin and atopy: role in atopic dermatitis and asthma. Int J Mol Sci. 2014;15(8):13482–93.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Campos FL, da Silva-Junior FP, de Bruin VM, de Bruin PF. Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2004;170(9):947–51.PubMedCrossRefGoogle Scholar
  43. 43.
    Waldhauser F, Steger H. Changes in melatonin secretion with age and pubescence. J Neural Transm Suppl. 1986;21:183–97.PubMedGoogle Scholar
  44. 44.
    Crowley SJ, Acebo C, Carskadon MA. Human puberty: salivary melatonin profiles in constant conditions. Dev Psychobiol. 2012;54(4):468–73.PubMedCrossRefGoogle Scholar
  45. 45.
    van Geijlswijk IM, Mol RH, Egberts TC, Smits MG. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology. 2011;216(1):111–20.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Richdale AL. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol. 1999;41(1):60–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Chamberlain RS, Herman BH. A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biol Psychiatry. 1990;28(9):773–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9(1):41–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett. 2000;21(1):31–4.PubMedGoogle Scholar
  50. 50.
    Melke J, Goubran Botros H, Chaste P, Betancur C, Nygren G, Anckarsater H, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13(1):90–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Nir I, Meir D, Zilber N, Knobler H, Hadjez J, Lerner Y. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord. 1995;25(6):641–54.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Tordjman S, Anderson GM, Bellissant E, Botbol M, Charbuy H, Camus F, et al. Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder. Psychoneuroendocrinology. 2012;37(12):1990–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Goldman SE, Adkins KW, Calcutt MW, Carter MD, Goodpaster RL, Wang L, et al. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord. 2014;44(10):2525–35.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Veatch OJ, Pendergast JS, Allen MJ, Leu RM, Johnson CH, Elsea SH, et al. Genetic variation in melatonin pathway enzymes in children with autism spectrum disorder and comorbid sleep onset delay. J Autism Dev Disord. 2015;45(1):100–10.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011;53(9):783–92.PubMedCrossRefGoogle Scholar
  56. 56.
    Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32(5):585–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145–50.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21(6):700–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Weiss MD, Salpekar J. Sleep problems in the child with attention-deficit hyperactivity disorder: defining aetiology and appropriate treatments. CNS Drugs. 2010;24(10):811–28.PubMedCrossRefGoogle Scholar
  60. 60.
    Barrett JR, Tracy DK, Giaroli G. To sleep or not to sleep: a systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(10):640–7.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry. 2006;45(5):512–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Bassell JL, Phan H, Leu R, Kronk R, Visootsak J. Sleep profiles in children with Down syndrome. Am J Med Genet A. 2015;167(8):1830–5.PubMedCentralCrossRefPubMedGoogle Scholar
  64. 64.
    Reiter RJ, Barlow-Walden L, Poeggeler B, Heiden SM, Clayton RJ. Twenty-four hour urinary excretion of 6-hydroxymelatonin sulfate in Down syndrome subjects. J Pineal Res. 1996;20(1):45–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Corrales A, Martinez P, Garcia S, Vidal V, Garcia E, Florez J, et al. Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome. J Pineal Res. 2013;54(3):346–58.PubMedCrossRefGoogle Scholar
  66. 66.
    Braam W, Didden R, Smits MG, Curfs LM. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008;23(6):649–54.PubMedCrossRefGoogle Scholar
  67. 67.
    Takaesu Y, Komada Y, Inoue Y. Melatonin profile and its relation to circadian rhythm sleep disorders in Angelman syndrome patients. Sleep Med. 2012;13(9):1164–70.PubMedCrossRefGoogle Scholar
  68. 68.
    Zhdanova IV, Wurtman RJ, Wagstaff J. Effects of a low dose of melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab. 1999;12(1):57–67.PubMedCrossRefGoogle Scholar
  69. 69.
    Wu Y, Bolduc FV, Bell K, Tully T, Fang Y, Sehgal A, et al. A Drosophila model for Angelman syndrome. Proc Natl Acad Sci U S A. 2008;105(34):12399–404.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Hancock E, O'Callaghan F, English J, Osborne JP. Melatonin excretion in normal children and in tuberous sclerosis complex with sleep disorder responsive to melatonin. J Child Neurol. 2005;20(1):21–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Hancock E, O'Callaghan F, Osborne JP. Effect of melatonin dosage on sleep disorder in tuberous sclerosis complex. J Child Neurol. 2005;20(1):78–80.PubMedCrossRefGoogle Scholar
  72. 72.
    Uberos J, Augustin-Morales MC, Molina Carballo A, Florido J, Narbona E, Munoz-Hoyos A. Normalization of the sleep-wake pattern and melatonin and 6-sulphatoxy-melatonin levels after a therapeutic trial with melatonin in children with severe epilepsy. J Pineal Res. 2011;50(2):192–6.PubMedGoogle Scholar
  73. 73.
    Elkhayat HA, Hassanein SM, Tomoum HY, Abd-Elhamid IA, Asaad T, Elwakkad AS. Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol. 2010;42(4):249–54.PubMedCrossRefGoogle Scholar
  74. 74.
    Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet. 1998;351(9111):1254.PubMedCrossRefGoogle Scholar
  75. 75.
    Philo R, Reiter RJ. Characterization of pinealectomy induced convulsions in the Mongolian gerbil (Meriones unguiculatus). Epilepsia. 1978;19(5):485–92.PubMedCrossRefGoogle Scholar
  76. 76.
    Rudeen PK, Philo RC, Symmes SK. Antiepileptic effects of melatonin in the pinealectomized Mongolian gerbil. Epilepsia. 1980;21(2):149–54.PubMedCrossRefGoogle Scholar
  77. 77.
    Fariello RG, Bubenik GA, Brown GM, Grota LJ. Epileptogenic action of intraventricularly injected antimelatonin antibody. Neurology. 1977;27(6):567–70.PubMedCrossRefGoogle Scholar
  78. 78.
    Molina-Carballo A, Munoz-Hoyos A, Sanchez-Forte M, Uberos-Fernandez J, Moreno-Madrid F, Acuna-Castroviejo D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics. 2007;38(3):122–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Goldberg-Stern H, Oren H, Peled N, Garty BZ. Effect of melatonin on seizure frequency in intractable epilepsy: a pilot study. J Child Neurol. 2012;27(12):1524–8.PubMedCrossRefGoogle Scholar
  80. 80.
    Gould EL, Loesch DZ, Martin MJ, Hagerman RJ, Armstrong SM, Huggins RM. Melatonin profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am J Med Genet. 2000;95(4):307–15.PubMedCrossRefGoogle Scholar
  81. 81.
    Galland BC, Elder DE, Taylor BJ. Interventions with a sleep outcome for children with cerebral palsy or a post-traumatic brain injury: a systematic review. Sleep Med Rev. 2012;16(6):561–73.PubMedCrossRefGoogle Scholar
  82. 82.
    Ayalon L, Borodkin K, Dishon L, Kanety H, Dagan Y. Circadian rhythm sleep disorders following mild traumatic brain injury. Neurology. 2007;68(14):1136–40.PubMedCrossRefGoogle Scholar
  83. 83.
    Kaufman Y, Tzischinsky O, Epstein R, Etzioni A, Lavie P, Pillar G. Long-term sleep disturbances in adolescents after minor head injury. Pediatr Neurol. 2001;24(2):129–34.PubMedCrossRefGoogle Scholar
  84. 84.
    Ponsford JL, Ziino C, Parcell DL, Shekleton JA, Roper M, Redman JR, et al. Fatigue and sleep disturbance following traumatic brain injury – their nature, causes, and potential treatments. J Head Trauma Rehabil. 2012;27(3):224–33.PubMedCrossRefGoogle Scholar
  85. 85.
    Yaeger K, Alhilali L, Fakhran S. Evaluation of tentorial length and angle in sleep-wake disturbances after mild traumatic brain injury. AJR Am J Roentgenol. 2013;202(3):614–8.CrossRefGoogle Scholar
  86. 86.
    Kemp S, Biswas R, Neumann V, Coughlan A. The value of melatonin for sleep disorders occurring post-head injury: a pilot RCT. Brain Inj. 2004;18(9):911–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Keegan LJ, Reed-Berendt R, Neilly E, Morrall MC, Murdoch-Eaton D. Effectiveness of melatonin for sleep impairment post paediatric acquired brain injury: evidence from a systematic review. Dev Neurorehabil. 2014;17(5):355–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Roberta M. Leu
    • 1
  1. 1.Pulmonary, Allergy/Immunology, Cystic Fibrosis and Sleep DivisionEmory University/Children’s Healthcare of AtlantaAtlantaUSA

Personalised recommendations